Sercan Çayırlı

Sercan Çayırlı


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2022 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
IÖIbrahim Özdemir
Ibrahim Özdemir
SOSefa Okar
Sefa Okar

27 January 2025 in Clinical Cardiology
Verified
Journal Article
Open access
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
SSSadi Can Sönmez
Sadi Can Sönmez
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
TKTarik Kivrak
Tarik Kivrak
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.

19 January 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
IÖIbrahim Özdemir
Ibrahim Özdemir
OIon behalf of the ANATOLIA-A. F. study investigators
on behalf of the ANATOLIA-A. F. study investigators

8 June 2026 in Kosuyolu Heart Journal
Verified
Journal Article
Open access
YIYUSUF INCI
YUSUF INCI
HBhasan ali barman
hasan ali barman
DODogac Oksen
Dogac Oksen
ODOmer Dogan
Omer Dogan
AEAbdullah Omer Ebeoğlu
Abdullah Omer Ebeoğlu
SDSait Mesut Doğan
Sait Mesut Doğan
Objective: Hemorrhagic complications continue to be a major clinical challenge among individuals with atrial fibrillation (AF) receiving direct-acting oral anticoagulants (DOACs). This research sought to evaluate and contrast the accuracy of various risk assessment models in forecasting bleeding incidents within this specific patient cohort. Methods: We enrolled 447 subjects diagnosed with AF who were prescribed DOAC therapy (including apixaban, dabigatran, edoxaban, or rivaroxaban). By retrospectively reviewing institutional electronic health records, we computed the ORBIT, ATRIA, and HEMORR 2 HAGES risk indices for each participant. The main outcome measures were defined as the occurrence of clinically relevant minor or major hemorrhages. Consequently, we analyzed how accurately these scoring systems could foresee the specified endpoints. Results: The cohort’s average age stood at 75.6±10.1 years, comprising predominantly women (62.2%). During a 12-month observation period, 6.7% of the participants (n=30) encountered one or more major hemorrhagic events. When forecasting severe bleeding, the ATRIA, ORBIT, and HEMORR 2 HAGES frameworks exhibited comparable predictive accuracies without any statistically notable variations. Upon conducting a multivariate logistic regression, independent variables linked to a heightened likelihood of bleeding encompassed prior hemorrhagic episodes (odds ratio [OR]: 3.101, p=0.019) and the presence of heart failure (OR: 2.028, p=0.009). In addition, anemia emerged as a significant factor (OR: 0.366, p=0.049), alongside elevated evaluations in both the HEMORR 2 HAGES (OR: 1.535, p=0.006) and ORBIT (OR: 1.849, p<0.014) scales. Conclusion: Both the ORBIT and HEMORR 2 HAGES models proved to be valuable independent indicators for future hemorrhagic complications. Integrating these tools into routine cardiovascular care can optimize therapeutic strategies and enhance the overall safety of AF patients on anticoagulation.

30 November 2020 in Turkish Journal of Sports Medicine
Verified
Journal Article
Open access
AKAlper Kartal
Alper Kartal
EEEsin Ergin
Esin Ergin
SÇSercan Çayırlı
Sercan Çayırlı
HGHasan Güngör
Hasan Güngör
ABAbraham Samuel Babu
Abraham Samuel Babu

1 December 2021 in Journal of Clinical and Analytical Medicine
Verified
Journal Article
Closed access
CZCemil Zencir
Cemil Zencir
SÇSercan Çayırlı
Sercan Çayırlı
SGSevil GülAştI
Sevil GülAştI
ATAhmet Kenan TürKdoğaN
Ahmet Kenan TürKdoğaN
CAÇaGdaş AkgülLü
ÇaGdaş AkgülLü
HGHasan GünGör
Hasan GünGör